Skip to main content
. Author manuscript; available in PMC: 2021 Nov 23.
Published in final edited form as: Sci Transl Med. 2021 Mar 3;13(583):eabc8980. doi: 10.1126/scitranslmed.abc8980

Figure 3. Teplizumab treatment was associated with increased average on-study C-peptide AUC.

Figure 3.

Boxplot displaying median and interquartile ranges for average on-study OGTT C-peptide AUC mean for participants from placebo and teplizumab treated groups. An ANCOVA model including baseline C-peptide AUC and age showed that treatment was associated with higher average on-study C-peptide AUC (p=0.009).